Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

(2021) Justin F Gainor et al.   LANCET ONCOLOGY

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

(2021) Vivek Subbiah et al.   Lancet Diabetes & Endocrinology

Tumour-agnostic therapies

(2020) Ann-Marie Looney et al.   NATURE REVIEWS DRUG DISCOVERY

Advances in Targeting RET-Dependent Cancers

(2020) Vivek Subbiah et al.   Cancer Discovery

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

(2020) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2019) S Filetti et al.   ANNALS OF ONCOLOGY

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Precision Targeted Therapy with BLU-667 for RET -Driven Cancers

(2018) Vivek Subbiah et al.   Cancer Discovery

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced,RET-altered solid tumors

(2018) Vivek Subbiah et al.   CANCER RESEARCH

RET rearrangements are actionable alterations in breast cancer

(2018) Bhavna S. Paratala et al.   Nature Communications

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients

(2016) Shumei Kato et al.   CLINICAL CANCER RESEARCH

Identification and characterization of RET fusions in advanced colorectal cancer

(2015) Anne-France Le Rolle et al.   Oncotarget

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

(2012) Doron Lipson et al.   NATURE MEDICINE

KIF5B-RET fusions in lung adenocarcinoma

(2012) Takashi Kohno et al.   NATURE MEDICINE

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE